May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Topical Cyclosporine 0.05% for the Treatment of Chronic, Active Ocular Rosacea
Author Affiliations & Notes
  • H.D. Perry
    Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, NY
  • J.R. Wittpenn
    Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, NY
  • G. D'Aversa
    Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, NY
  • E.D. Donnenfeld
    Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, NY
  • Footnotes
    Commercial Relationships  H.D. Perry, Allergan C; J.R. Wittpenn, Allergan C; G. D'Aversa, None; E.D. Donnenfeld, Allergan C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2660. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.D. Perry, J.R. Wittpenn, G. D'Aversa, E.D. Donnenfeld; Topical Cyclosporine 0.05% for the Treatment of Chronic, Active Ocular Rosacea . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2660. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Evaluation of topical Cyclosporine 0.05% in treating chronic, active ocular rosacea unresponsive to standard treatment. Methods: 55 patients placed on topical Cyclosporine for a minimum of 6 months and followed for an average of 11.8 months (range 6 to 17). Evaluation combined patient symptoms and clinical exam including supravital staining. Results: 11 patients (20%) withdrew before 6 months for poor response. 17 patients (31%) reported mild (4) to moderate (13) relief of symptoms with improvement in clinical exam. 25 patients (45%) had significant (17) or complete (8) resolution. Only 2 patients were able to discontinue medication without recurrence. 2 patients (4%) developed recurrence on treatment despite initial improvement. Among responsive patients, at last follow–up, 30 patients (71%) were off all other medications and 12 patients (29%) were still taking low dose tetracycline. Conclusions: Topical Cyclosporine is efficacious for the treatment of ocular rosacea unresponsive to standard therapy. The majority of responsive patients can eventually discontinue oral medications. Most patients, however, require prolonged treatment with topical Cyclosporine 0.05% to maintain control of the condition.

Keywords: cyclosporine • keratitis • autoimmune disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×